{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:59:16Z","timestamp":1776103156325,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017570","name":"Commonwealth Serum Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nefroe.2026.501454","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:32:05Z","timestamp":1772742725000},"page":"501454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of patiromer in patients with hyperkalaemia: A retrospective study from the Valencian Community"],"prefix":"10.1016","volume":"46","author":[{"given":"Francesc","family":"Moncho-Franc\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gonzales-Candia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Perez-Silvestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Sanchez-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Garcia-Maset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonay","family":"Pantoja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Carbonell-Asins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gimenez-Civera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"De la Espriella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Puchades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1134-9051","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nefroe.2026.501454_bib0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a kidney disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.nefroe.2026.501454_bib0010","first-page":"1610","article-title":"Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes\u2013a Danish population-based cohort study","volume":"33","author":"Thomsen","year":"2018","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc."},{"issue":"37","key":"10.1016\/j.nefroe.2026.501454_bib0015","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J."},{"issue":"4S","key":"10.1016\/j.nefroe.2026.501454_bib0020","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.nefroe.2026.501454_bib0025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail."},{"issue":"5","key":"10.1016\/j.nefroe.2026.501454_bib0030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J Am Soc Nephrol JASN."},{"issue":"8","key":"10.1016\/j.nefroe.2026.501454_bib0035","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"1","key":"10.1016\/j.nefroe.2026.501454_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12882-019-1228-y","article-title":"The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease","volume":"20","author":"Evans","year":"2019","journal-title":"BMC Nephrol."},{"issue":"41","key":"10.1016\/j.nefroe.2026.501454_bib0045","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J."},{"issue":"3","key":"10.1016\/j.nefroe.2026.501454_bib0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.nefroe.2026.501454_bib0055","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J."},{"issue":"2","key":"10.1016\/j.nefroe.2026.501454_bib0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.nefroe.2026.501454_bib0065","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods."},{"issue":"4","key":"10.1016\/j.nefroe.2026.501454_bib0070","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol."},{"issue":"8","key":"10.1016\/j.nefroe.2026.501454_bib0075","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail."},{"issue":"22","key":"10.1016\/j.nefroe.2026.501454_bib0080","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc."},{"issue":"2","key":"10.1016\/j.nefroe.2026.501454_bib0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00325481.2019.1706920","article-title":"Real-world management of hyperkalemia with patiromer among United States Veterans","volume":"132","author":"Kovesdy","year":"2020","journal-title":"Postgrad Med"},{"issue":"50","key":"10.1016\/j.nefroe.2026.501454_bib0090","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032367","article-title":"Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease","volume":"101","author":"Pinnell","year":"2022","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"10.1016\/j.nefroe.2026.501454_bib0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ckj\/sfab159","article-title":"Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease","volume":"15","author":"Trevisan","year":"2022","journal-title":"Clin Kidney J."},{"issue":"11 Suppl","key":"10.1016\/j.nefroe.2026.501454_bib0100","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care."},{"issue":"9","key":"10.1016\/j.nefroe.2026.501454_bib0105","first-page":"1518","article-title":"Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study","volume":"35","author":"Laureati","year":"2020","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc."},{"key":"10.1016\/j.nefroe.2026.501454_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CNCS109782","article-title":"Case report: patiromer-induced hypercalcemia","volume":"7","author":"Wiederkehr","year":"2019","journal-title":"Clin Nephrol Case Stud."},{"key":"10.1016\/j.nefroe.2026.501454_bib0115","article-title":"Patiromer acetate induced hypercalcemia: an unreported adverse effect","volume":"2019","author":"Bhattarai","year":"2019","journal-title":"Case Rep Nephrol."},{"issue":"16","key":"10.1016\/j.nefroe.2026.501454_bib0120","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.3390\/jcm10163756","article-title":"A rare case of patiromer induced hypercalcemia","volume":"10","author":"Kanduri","year":"2021","journal-title":"J Clin Med."},{"issue":"17","key":"10.1016\/j.nefroe.2026.501454_bib0125","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"10.1016\/j.nefroe.2026.501454_bib0130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nefro.2023.05.004","article-title":"Documento de consenso sobre el abordaje de la hiperpotasemia","volume":"43","author":"Ortiz","year":"2023","journal-title":"Nefrolog\u00eda."},{"issue":"6","key":"10.1016\/j.nefroe.2026.501454_bib0135","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.nefro.2022.08.007","article-title":"Impacto econ\u00f3mico del uso de patiromer en enfermedad renal cr\u00f3nica o insuficiencia card\u00edaca para el tratamiento de la hiperpotasemia cr\u00f3nica en Espa\u00f1a","volume":"43","author":"de Sequera","year":"2023","journal-title":"Nefrolog\u00eda."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426000489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426000489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:55:35Z","timestamp":1776099335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251426000489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2013251426000489"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501454","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use of patiromer in patients with hyperkalaemia: A retrospective study from the Valencian Community","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2025.501454","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501454"}}